Skip to main content
SpringerLink
Log in

Radiation Biology of Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 362 Accesses

Abstract

Radiobiology is central to an understanding of the principles of radiotherapy today. In the early twentieth century, the use of large, single doses of radiation, or hypofractionation, declined as evidence mounted that these doses caused considerable damage to normal tissues. Based on radiobiology, treatments then shifted toward smaller daily doses over a period of several weeks as a way to reduce this damage yet still achieve tumor control. A paradigm shift toward hypofractionation occurred again in the early twenty-first century as advances in technology now enable high-dose radiation to more precisely target the tumor while minimizing the amount of normal tissues exposed. In this chapter, we explore the basic tenets of radiation biology in order to understand the rationale behind these vastly different approaches as they apply specifically to the treatment of lung cancer. We also examine ways to exploit the radiobiology of lung cancer by using various strategies with a focus on moderate hypofractionation, stereotactic ablative radiation therapy, and tumor hypoxia. We conclude with a discussion on the biology of combining immunotherapy with radiation in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Antonia SJ et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

    Google Scholar 

  • Baumann M et al (2011) Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 100:76–85

    Google Scholar 

  • Belani CP et al (2005) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760–3767

    Google Scholar 

  • Bentzen SM, Harari PM, Bernier J (2007) Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4:172–180

    Google Scholar 

  • Bernstein MB, Krishnan S, Hodge JW, Chang JY (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13:516–524

    Google Scholar 

  • Bezjak A et al (2019) Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 37:1316–1325

    Google Scholar 

  • Bonfili P et al (2010) Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I–II non-small-cell lung cancer. Lung Cancer 67:81–85

    Google Scholar 

  • Bourhis J et al (2019) Treatment of a first patient with FLASH-radiotherapy. Radiother Oncol 139:18–22

    Google Scholar 

  • Brada M, Pope A, Baumann M (2015) SABR in NSCLC—the beginning of the end or the end of the beginning? Radiother Oncol 114:135–137

    Google Scholar 

  • Brahmer J et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Google Scholar 

  • Brenner DJ, Hlatky LR, Hahnfeldt PJ, Huang Y, Sachs RK (1998) The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res 150:83–91

    Google Scholar 

  • Brown JM, Koong AC (2008) High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys 71:324–325

    Google Scholar 

  • Brown JM, Diehn M, Loo BW Jr (2010) Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 78:323–327

    Google Scholar 

  • Brown JM, Brenner DJ, Carlson DJ (2013) Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85:1159–1160

    Google Scholar 

  • Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88:254–262

    Google Scholar 

  • Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79:1188–1195

    Google Scholar 

  • Chang JY et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637

    Google Scholar 

  • Chaudhuri AA et al (2015) Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 89:50–56

    Google Scholar 

  • Chen LD et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol 100:916–925

    Google Scholar 

  • Cheung PC et al (2002) Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:1014–1023

    Google Scholar 

  • Chicas-Sett R et al (2019) Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a systematic review. Int J Mol Sci 20

    Google Scholar 

  • Cho KH et al (2009) A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 74:1397–1404

    Google Scholar 

  • Cox JD et al (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543–1555

    Google Scholar 

  • Cox JD et al (1991) Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08. Am J Clin Oncol 14:280–284

    Google Scholar 

  • Curran WJ Jr et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460

    Google Scholar 

  • De Los Santos J et al (2013) Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery. Int J Radiat Oncol Biol Phys 87:33–45

    Google Scholar 

  • Deng HY et al (2017) Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 51:203–210

    Google Scholar 

  • Din OS et al (2013) Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 109:8–12

    Google Scholar 

  • Elkind MM, Whitmore GF, American Institute of Biological Sciences (1967) The radiobiology of cultured mammalian cells. Gordon and Breach, New York

    Google Scholar 

  • Faria SL et al (2006) Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol 1:42

    Google Scholar 

  • Favaudon V et al (2014) Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med 6:245ra293

    Google Scholar 

  • Filatenkov A et al (2015) Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21:3727–3739

    Google Scholar 

  • Foster CC et al (2019) Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol 14:18

    Google Scholar 

  • Fowler JF (1991) Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment—continually rapid proliferation unmasked. Radiother Oncol 22:156–158

    Google Scholar 

  • Fu S, Jiang GL, Wang LJ (1994) [Hyperfractionated irradiation for non-small cell lung cancer (NSCLC)—a phase III clinical trial]. Zhonghua Zhong Za Zhi 16, 306–309

    Google Scholar 

  • Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8:89–91

    Google Scholar 

  • Garcia-Barros M et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159

    Google Scholar 

  • Gauden S, Ramsay J, Tripcony L (1995) The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 108:1278–1282

    Google Scholar 

  • Giuliani M et al (2018) SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial. Clin Lung Cancer 19:e529–e532

    Google Scholar 

  • Graves EE et al (2010) Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 16:4843–4852

    Google Scholar 

  • Guckenberger M et al (2017) ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 124:11–17

    Google Scholar 

  • Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6:2036–2043

    Google Scholar 

  • Hall EJ, Giaccia AJ (2012) Radiobiology for the radiologist. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  • Herbst RS et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

    Google Scholar 

  • Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R (2017) Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunol Immunother 66:281–298

    Google Scholar 

  • Iyengar P et al (2016) A phase III randomized study of image guided conventional (60 Gy/30 fx) versus accelerated, hypofractionated (60 Gy/15 fx) radiation for poor performance status stage II and III NSCLC patients-an interim analysis. Int J Radiat Oncol 96:E451–E451

    Google Scholar 

  • Kelada OJ et al (2018) High single doses of radiation may induce elevated levels of hypoxia in early-stage non-small cell lung cancer tumors. Int J Radiat Oncol Biol Phys 102:174–183

    Google Scholar 

  • Kirkpatrick JP, Meyer JJ, Marks LB (2008) The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18:240–243

    Google Scholar 

  • Kreuzaler P, Watson CJ (2012) Killing a cancer: what are the alternatives? Nat Rev Cancer 12:411–424

    Google Scholar 

  • Lan J et al (2018) Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy. Int J Radiat Oncol Biol Phys 101:74–87

    Google Scholar 

  • Le QT et al (2004) Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 10:5418–5424

    Google Scholar 

  • Le QT et al (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12:1507–1514

    Google Scholar 

  • Le QT et al (2009) Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol 27:3014–3019

    Google Scholar 

  • Lehrer EJ et al (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104–112

    Google Scholar 

  • Lester JF, Macbeth FR, Brewster AE, Court JB, Iqbal N (2004) CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 45:237–242

    Google Scholar 

  • Lewanski CR, Gullick WJ (2001) Radiotherapy and cellular signalling. Lancet Oncol 2:366–370

    Google Scholar 

  • Lin SH et al (2013) Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 105:686–693

    Google Scholar 

  • Lugade AA et al (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516–7523

    Google Scholar 

  • Maguire J et al (2014) SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer 50:2939–2949

    Google Scholar 

  • Marconi R, Strolin S, Bossi G, Strigari L (2017) A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger? PLoS One 12:e0171559

    Google Scholar 

  • Mauguen A et al (2012) Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 30:2788–2797

    Google Scholar 

  • Montay-Gruel P et al (2017) Irradiation in a flash: unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s. Radiother Oncol 124:365–369

    Google Scholar 

  • Montay-Gruel P et al (2018) X-rays can trigger the FLASH effect: ultra-high dose-rate synchrotron light source prevents normal brain injury after whole brain irradiation in mice. Radiother Oncol 129:582–588

    Google Scholar 

  • Nahum AE, Uzan J (2012) (Radio)biological optimization of external-beam radiotherapy. Comput Math Methods Med 2012:329214

    MathSciNet  Google Scholar 

  • Oh D, Ahn YC, Kim B, Pyo H (2013) Hypofractionated three-dimensional conformal radiation therapy alone for centrally located cT1–3N0 non-small-cell lung cancer. J Thorac Oncol 8:624–629

    Google Scholar 

  • Osti MF et al (2013) Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85:e157–e163

    Google Scholar 

  • Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066–4074

    Google Scholar 

  • Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10–21

    Google Scholar 

  • Owen D, Sio TT (2020) Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors. J Thorac Dis 12:7024–7031

    Google Scholar 

  • Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70:847–852

    Google Scholar 

  • Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177:311–327

    Google Scholar 

  • Perez CA et al (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744–2753

    Google Scholar 

  • Pinnamaneni R et al (2017) Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer. J Clin Oncol 35

    Google Scholar 

  • Postow MA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931

    Google Scholar 

  • Powell S, Cooke J, Parsons C (1990) Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 18:213–220

    Google Scholar 

  • Qiu B, Aili A, Xue L, Jiang P, Wang J (2020) Advances in radiobiology of stereotactic ablative radiotherapy. Front Oncol 10:1165

    Google Scholar 

  • Samstein R, Rimner A, Barker CA, Yamada Y (2017) Combined immune checkpoint blockade and radiation therapy: timing and dose fractionation associated with greatest survival duration among over 750 treated patients. Int J Radiat Oncol 99:S129–S130

    Google Scholar 

  • Saunders M et al (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350:161–165

    Google Scholar 

  • Saunders M et al (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52:137–148

    Google Scholar 

  • Sause WT et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205

    Google Scholar 

  • Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310

    Google Scholar 

  • Seydel HG et al (1985) Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: preliminary report of a RTOG Pilot Study. Int J Radiat Oncol Biol Phys 11:1841–1847

    Google Scholar 

  • Singh AK et al (2019) One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys 105:752–759

    Google Scholar 

  • Slotman BJ, Antonisse IE, Njo KH (1996) Limited field irradiation in early stage (T1–2N0) non-small cell lung cancer. Radiother Oncol 41:41–44

    Google Scholar 

  • Soliman H et al (2011) Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 79:459–465

    Google Scholar 

  • Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW (2014) Radiobiological basis of SBRT and SRS. Int J Clin Oncol 19:570–578

    Google Scholar 

  • Tekatli H, Senan S, Dahele M, Slotman BJ, Verbakel WF (2015) Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and long-term clinical outcomes. Radiother Oncol 117:64–70

    Google Scholar 

  • Theelen W et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5:1276–1282

    Google Scholar 

  • Timmerman R et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839

    Google Scholar 

  • Timmerman R et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076

    Google Scholar 

  • Timmerman RD et al (2018) Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 Trial. JAMA Oncol 4:1263–1266

    Google Scholar 

  • Urbanic JJ et al (2018) Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys 101:177–185

    Google Scholar 

  • Van Putten LM, Kallman RF (1968) Oxygenation status of a transplantable tumor during fractionated radiation therapy. J Natl Cancer Inst 40:441–451

    Google Scholar 

  • Vansteenkiste J et al (2014) 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 25:1462–1474

    Google Scholar 

  • Videtic GM et al (2015) A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 93:757–764

    Google Scholar 

  • Videtic GM et al (2019) Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 103:1077–1084

    Google Scholar 

  • Vokes EE et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29:959–965

    Google Scholar 

  • Walshaw RC, Honeychurch J, Illidge TM (2016) Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy? Br J Radiol 89:20160472

    Google Scholar 

  • Wang HH et al (2018) Ablative hypofractionated radiation therapy enhances non-small cell lung cancer cell killing via preferential stimulation of necroptosis in vitro and in vivo. Int J Radiat Oncol Biol Phys 101:49–62

    Google Scholar 

  • Westover KD et al (2015) Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. Int J Radiat Oncol Biol Phys 93:72–81

    Google Scholar 

  • Williamson SK et al (2005) Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23:9097–9104

    Google Scholar 

  • Xing D, Siva S, Hanna GG (2019) The abscopal effect of stereotactic radiotherapy and immunotherapy: fool’s gold or el dorado? Clin Oncol (R Coll Radiol) 31:432–443

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Jose G. Bazan

Authors
  1. Jose G. Bazan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose G. Bazan .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bazan, J.G. (2023). Radiation Biology of Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_306

Download citation

  • DOI: https://doi.org/10.1007/174_2022_306

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation